Liquid Biotech USA, Inc. Information

Liquid Biotech USA, Inc. is a cancer diagnostic company that has developed a non-invasive blood test, a liquid biopsy, to monitor cancer as it develops and is treated during therapy. The advantages of our approach include the ability to take serial biopsies with little risk, isolate live cancer cells and obtain genetic information from those cells that the oncologist can use to direct therapy (personalized medicine). Our assay is based on over-expression of telomerase activity, considered a universal marker for cancer; competitors rely on cell surface markers for detection that are not always reliable. Because our assay is non-invasive, serial monitoring of patients’ disease status is possible; when coupled with isolation of live cells/genetic analysis the result is a therapy that can be personalized for the cancer patient. Our technology is broad and can be applied to diagnosis/prognosis of cancer, personalized medicine development, companion diagnostics and cancer driver gene discovery and resistance mechanisms that arise during therapy. The business model is to partner with pharma and biotech companies in the technology areas described above; typical business structures will include technology assess fees, milestone and royalty payments on developed tests.